Your Abstract Submission Has Been Received

Print this page

You have submitted the following abstract to 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers. Receipt of this notice does not guarantee that your submission was complete or free of errors.

Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results from the Phase 3 Asclepios I/II Trials

Silvia R. Delgado, MD, Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, Enrique Alvarez, MD, PhD, Department of Neurology, Rocky Mountain MS Center at the University of Colorado Anschutz Medical Center, University of Colorado, Aurora, CO, Eric Thouvenot, MD PhD, Department of Neurology, Centre Hospitalier Universitaire (CHU) Nîmes, University of Montpellier, Nîmes, France; Institut de Génomique Fonctionnelle, UMR, Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France, Annette F. Okai, MD, FAAN, North Texas Institute of Neurology and Headache, Plano, TX, Alit Bhatt, MBBS, Novartis Healthcare Pvt. Ltd., Hyderabad, India, Wenjia Wei, PhD, Novartis Pharma AG, Basel, Switzerland, Jason Freeman, MD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, NJ and Tjalf Ziemssen, MD, PhD, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany

Abstract Text:
Background: In the phase 3 ASCLEPIOS I/II trials (ofatumumab vs teriflunomide), baseline serum neurofilament light chain (sNfL) levels were prognostic for on-study lesion formation and brain volume loss. However, the prognostic value of sNfL for future disease activity among diverse racial/ethnic subgroups from the trials has yet to be explored.

Objectives: To evaluate the prognostic value of baseline sNfL for future magnetic resonance imaging disease activity in diverse racial/ethnic subpopulations (Asian, Black, and other) of people with relapsing multiple sclerosis (pwRMS) in ASCLEPIOS I/II.

Methods: A baseline sNfL cutoff was predefined by the median sNfL value across the ASCLEPIOS I/II studies, and participants were stratified into high (≥9.3 pg/mL) and low (<9.3 pg/mL) groups irrespective of treatment received. The prognostic value of high vs low baseline sNfL for the annualized rate of new/enlarging T2 (neT2) lesions was assessed in the overall population, and White and racial/ethnic subgroups from ASCLEPIOS I/II. neT2 lesion number on the last available scan (relative to baseline scan) was analyzed using a negative binomial model with time (in years) between the 2 scans as offset, adjusting for baseline sNfL groups. The prognostic value was assessed via the lesion rate ratio (RR) attained using this single cutoff threshold for high vs low sNfL.

Results: Of the 1882 participants randomized, 1678 (89.2%) had baseline sNfL and neT2 lesion data available. Annualized mean rate of neT2 lesions for participants with high/low baseline sNfL levels in the Asian (n=31/29), Black (n=29/26), and other (n=39/34) subgroups were 2.59/0.97 (RR 2.68; p=0.042), 5.10/2.04 (RR 2.50; p=0.061), and 7.79/3.07 (RR 2.54; p=0.029), respectively; values for the White subgroup (n=738/752) and overall population (n=837/841) were 3.91/1.83 (RR 2.14; p<0.001) and 4.08/1.85 (RR 2.20; p<0.001), respectively.

Conclusions: Baseline sNfL levels were prognostic for neT2 lesion development in all pwRMS, including those of diverse racial/ethnic subpopulations.

Title:
Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results from the Phase 3 Asclepios I/II Trials

Submitter's E-mail Address:
molly.burke@envisionpharma.com

Preferred Presentation Format:
Poster

Category:
Non-imaging biomarkers

Has this abstract been presented/published elsewhere prior to this meeting?:
No

Have you simultaneously submitted this abstract to another organization for consideration?:
Yes

Simultaneous submission details:
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the American Academy of Neurology (AAN) 2024. ACTRIMS Forum 2024 will be held February 29-March 2, 2024 and AAN will be held April 13-18, 2024.

Would you give CMSC and International Journal of MS Care the first preference to any article that is submitted for publication based on this abstract presentation?:
No

Category: Non-imaging biomarkers

Keywords:
Disease-modifying treatments in MS

First Presenting Author

Presenting Author

Silvia Delgado, MD
Email: sdelgado1@med.miami.edu -- Will not be published
Alternate Email: sdelgado1@med.miami.edu -- Will not be published

University of Miami, Miller School of Medicine
Department of Neurology
Miami FL
USA

Click to view Conflict of Interest Disclosure

Second Author

Enrique Alvarez, MD, PhD
Email: enrique.alvarez@cuanschutz.edu -- Will not be published

Department of Neurology, Rocky Mountain MS Center at the University of Colorado
Anschutz Medical Center, University of Colorado
Aurora CO
USA

Click to view Conflict of Interest Disclosure

Third Author

Eric Thouvenot, MD PhD
Email: eric.thouvenot@chu-nimes.fr -- Will not be published

Centre Hospitalier Universitaire (CHU) Nîmes, University of Montpellier
Department of Neurology
Nîmes
France
Institut de Génomique Fonctionnelle, UMR, Institut National de la Santé et de la Recherche Médicale (INSERM)
Montpellier
France

Click to view Conflict of Interest Disclosure

Fourth Author

Annette Okai, MD, FAAN
Email: aokaimd@outlook.com -- Will not be published

North Texas Institute of Neurology and Headache
Plano TX
USA

Click to view Conflict of Interest Disclosure

Fifth Author

Alit Bhatt, MBBS
Email: alit.bhatt@novartis.com -- Will not be published

Novartis Healthcare Pvt. Ltd.
Hyderabad
India

Click to view Conflict of Interest Disclosure

Sixth Author

Wenjia Wei, PhD
Email: wenjia.wei@novartis.com -- Will not be published

Novartis Pharma AG
Basel
Switzerland

Click to view Conflict of Interest Disclosure

Seventh Author

Jason Freeman, MD, MBA
Email: jason.freeman@novartis.com -- Will not be published

Novartis Pharmaceuticals Corporation
East Hanover NJ
USA

Click to view Conflict of Interest Disclosure

Eighth Author

Tjalf Ziemssen, MD, PhD
Email: Tjalf.Ziemssen@uniklinikum-dresden.de -- Will not be published

University Clinic Carl-Gustav Carus
Department of Neurology

Dresden
Germany

Click to view Conflict of Interest Disclosure

First Contact

Molly Burke, BA
Email: molly.burke@envisionpharma.com -- Will not be published
Alternate Email: EnvisionNovartisNeurology@envisionpharma.com -- Will not be published

Envision
Philadelphia PA
USA

If necessary, you can make changes to your abstract submission.

To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.
Or point your browser to /cmsc/reminder.cgi to have that URL mailed to you again. Your username/password are 9508/492918.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

Tell us what you think of the abstract submission process

Home Page